SAFETY & HEALTH INDEMNITY Buyer acknowledges that Seller has furnished to Buyer Material Safety Data Sheets as required under applicable laws and regulations, which include warnings together with safety and health information concerning the Product and/or the containers for such Product. DATA PROTECTION Buyer hereby agrees that any data in relation with the business relationship between Buyer and Seller may be processed by Seller, in compliance with applicable laws and regulations. 15.

PRODUCT BULLETIN reSound™ REC Recycled Content TPEs Sustainable TPEs for automotive interiors The demands for improved sustainability continue to drive innovation and change across the transportation industry. Developed in response to the increased need for sustainable material alternatives, reSound™ REC TPEs provide comparable performance to traditional fossil-based grades, and support goals for reduced waste and carbon emissions. Designed to meet common OEM requirements, these recycled grades offer similar aesthetics to prime TPEs.

THERMOPLASTIC ELASTOMERS North America Portfolio PRODUCT SELECTION GUIDE GENERAL PROPERTIES REGULATORY OVERMOLDING PROCESS FEATURES Appearance Hardness Specific Gravity Food Contact UL 94 Suitable Substrates Injection Extrusion ASTM (Shore) ASTM (D792) reSound™ REC Recycled Content Series VX2800-9003 C Natural 47A 0.94 - - PP ✔ - 25% post-consumer recycled (PCR) content (PVB from windshields and laminated glass); 1.77 cradle-to-gate product carbon footprint (PCF) VX2800-9004 C Natural 54A 0.95 - - PP ✔ - 25% PCR content (PVB from windshields and laminated glass) VX2800-0001 I Black 65A 0.89 - - PP ✔ - 25% post-industrial recycled (PIR) content VX2800-0001 I Natural 65A 0.89 - - PP ✔ - 25% PIR content VX2800-0001 C Black 65A 0.89 - - PP ✔ - 25% PCR content (ocean plastics) VX2800-0002 I Black 65A 0.88 - - PP ✔ - 40% PIR content VX2800-0003 C Gray 65A 0.88 ✔ - PP ✔ - 25% PCR/PIR content (food packaging) with application specific FDA rating VX0100-0001 AR I Black 79A 1.05 - - PC, ABS, PC/ABS ✔ - 30% PIR content reSound™ BIO Bio-based Series RS7900-0001 30N Natural 31A 1.00 - - PP ✔ - 35% bio-derived content (Gen 1 biomass) RS7900-0001 45N Natural 48A 1.11 - - PP ✔ - 35% bio-derived content (Gen 1 biomass) RS7900-0001 60N Natural 59A 1.11 - - PP ✔ - 35% bio-derived content (Gen 1 biomass) RS7900-0001 70N Natural 69A 1.09 - - PP ✔ - 35% bio-derived content (Gen 1 biomass) RS2800-0001 30N Natural 33A 0.85 - - PP ✔ - 50–60% bio-derived content (Gen 1 biomass) RS2800-0001 45N Natural 49A 0.85 - - PP ✔ - 50–60% bio-derived content (Gen 1 biomass) RS2800-0001 60N Natural 63A 0.87 - - PP ✔ - 50–60% bio-derived content (Gen 1 biomass) RS2800-0001 70N Natural 71A 0.86 - - PP ✔ - 50–60% bio-derived content (Gen 1 biomass) reSound™ Ultra-Low Carbon Footprint Series RS0200-9001 80 Natural 80A 0.87 - - PP, LDPE ✔ - -0.40 cradle-to-gate PCF RS0200-9001 60 Natural 60A 0.86 - - PP, LDPE ✔ - -0.03 cradle-to-gate PCF FEATURED TPES FOR CONSUMER APPLICATIONS CO N SU M ER Avient’s specialty thermoplastic elastomers (TPEs) are formulated to meet countless performance, application and aesthetic demands. Backed by decades of TPE expertise, our team can help you choose the best polymer for your product or customize a material to meet your specific challenges. Contact Avient to tap into our expertise and learn more about our specialty TPEs.

artery tourniquet A RT E RY TO U R N I Q U E T M A N U FAC T U R E R G A S K E T O F R A D I A L A R T E R Y H E M O S T A T • Super soft feeling • Increased production efficiency by simple injection process • High transparency • Delivered a series of soft-touch TPEs capable of meeting the desired feel • Formulated solutions to comply with FDA regulation for skin contact • Provided easy molding and assembling by onsite technical and customized durometer Customized Versaflex™ TPEs KEY REQUIREMENTS WHY AVIENT?

Technical Data Sheets Safety Data Sheets Safety Data Sheets

However, the original TPE that the company selected caused issues during 2K molding. THE SOLUTION Avient was asked to suggest a suitable TPE for this application. For this manufacturer, another appealing aspect of working with this material was Avient’s dedicated TPE production line in Spain, which is used solely to manufacture TPEs for overmolding applications.

SNOWMOBILE OEM S N O W F L A P • Cold temperature flexibility and toughness • UV stability • Easily injection moldable • Offered a specialty TPE capable of performing well in demanding environments • Delivered a technology that supported a nearly 2-foot flow length for easy processing • Generated .udb file to help accelerate new designs • Collaborated with the molder and OEM for seamless product development and production OnFlex™ Thermoplastic Elastomer KEY REQUIREMENTS WHY AVIENT?

Use of Non-GAAP Measures Page 3 PolyOne Commodity to Specialty Transformation • Volume driven, commodity producer • Heavily tied to cyclical end markets • Performance largely dependent on non- controlling joint ventures 2000-2005 2006 - 2009 2010 – 2014 2015 and beyond • Steve Newlin appointed, Chairman, President and CEO • New leadership team appointed • Implementation of four pillar strategy • Focus on value based selling, investment in commercial resources and innovation to drive transformation • 18 consecutive quarters of double- digit adjusted EPS growth • Shift to faster growing, high margin, less cyclical end markets • Key acquisitions propel current and future growth, as well as margin expansion • Established aggressive 2015 targets • Continue specialty transformation • Targeting $2.50 Adjusted EPS by 2015, nearly double 2013 EPS • Drive double digit operating income and adjusted EPS growth Confirmation of Our Strategy The World’s Premier Provider of Specialized Polymer Materials, Services and Solutions Specialization Globalization Operational Excellence Commercial Excellence -150.00% -50.00% 50.00% 150.00% 250.00% 350.00% 450.00% PolyOne S&P 500 Russell 2000 Dow Jones Chemical All time high of $39.28 April 4th, 2014 • 18 consecutive quarters of double digit EPS growth • 49% CAGR adjusted EPS expansion 2006-2013 • 2013 stock price increased 73% versus 30% growth in the S&P • More than seven fold increase in market cap: $0.5b $3.6b Strategy and Execution Drive Results Page 6 Appliance 4% Building & Construction 13% Wire & Cable 9% Electrical & Electronics 5% Consumer 10%Packaging 16% Industrial 12% HealthCare 11% Transportation 18% Misc. 2% 0.12 0.27 0.21 0.13 0.68 0.82 1.00 1.31 2.50 $0.00 $0.25 $0.50 $0.75 $1.00 $1.25 $1.50 $1.75 $2.00 $2.25 $2.50 2006 2007 2008 2009 2010 2011 2012 2013 2015 Target A dj us te d Ea rn in gs P er S ha re 2013 Revenues: $3.8 Billion End Markets 2013 Revenues: $3.8 Billion EPS Page 7 PolyOne At A Glance United States 67% Europe 14% Canada 7% Asia6% Latin America 6% Specialty 54% PP&S 18% Distribution 28% Mix Shift Highlights Specialty Transformation Page 8 Old PolyOne Transformation *Operating Income excludes corporate charges and special items 2% 34% 43% 62% 64% 0% 20% 40% 60% 80% 100% 2005 2008 2010 2013 Q1 2014 2015 % o f O pe ra tin g In co m e* JV's Performance Products & Solutions Distribution Specialty 65-75% Specialty OI $5M $46M $87M $195M $60M Target 2015 Target Proof of Performance & 2015 Goals Page 9 2006 Q1 2014 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 13.8% 12 – 16% Global Specialty Engineered Materials 1.1% 11.6% 12 – 16% Designed Structures & Solutions -- 6.5% 8 – 10% Performance Products & Solutions 5.5% 7.7% 9 – 12% Distribution 2.6% 6.1% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 64% 65 – 75% 3) ROIC* (after-tax) 5.0% 9.4% 15% 4) Adjusted EPS Growth N/A 42% Double DigitExpansion *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period Bridge to $2.50 Adjusted EPS by 2015 2015 EPS: $2.50 2013 EPS: $1.31 Continued Gross Margin Expansion Mergers & Acquisitions Spartech Accretion Incremental share buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Several Levers to Drive Growth Mid single digit revenue CAGR Innovation Drives Earnings Growth $20.3 $52.3 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* *Percentage of Specialty Platform revenue from products introduced in last five years Page 11 14.3% 30.7% 2006 2013 Specialty Platform Gross Margin % 19.5% 42.0% 2006 Q1 2014 Healthcare Consumer Packaging and Additive Technology Transportation Page 12 Unique and Innovative Solutions https://www.dropbox.com/sh/dwe4t8aacvhb8ui/uD3p_bdglP/Presentation revise pics/GLS Beverage can closure XO 2.jpg https://www.dropbox.com/sh/dwe4t8aacvhb8ui/-YgkycKypw/Anti-Counterfeiting release & images/GN1979.JPG 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2014 Pension Funding** As of March 31, 2014 Debt Maturities & Pension Funding – 3/31/14 Net Debt / EBITDA* = 1.9x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Debt Maturities As of March 31, 2014 ($ millions) Coupon Rates: 7.500% 7.375% 5.250% ** includes US-qualified pension plans only *TTM 3/31/2014 Free Cash Flow and Strong Balance Sheet Fund Investment / Shareholder Return $0.16 $0.20 $0.24 $0.32 $0.10 $0.20 $0.30 $0.40 2011 2012 2013 2014 Annual Dividend  Expanding our sales, marketing, and technical capabilities  Investing in operational and initiatives that drive profitability growth  Manufacturing realignment  Targets that expand our: • Specialty offerings • End market presence • Geographic footprint • Operating Margin  Synergy opportunities  Adjacent material solutions  Repurchased 1.4 million shares in Q1 2014  Repurchased 6.4 million shares since April 2013  13.6 million shares are available for repurchase under the current authorization Organic Growth Acquisitions Share Repurchases Dividends The New PolyOne: A Specialty Growth Company Why Invest In PolyOne?  Strong past performance demonstrates that our strategy and execution are working  Megatrends and emerging opportunities align with our strengths  Innovation and services provide differentiation, incremental pricing power, and competitive advantage  Strong and proven management team driving growth and performance  Addressable market exceeds $40 billion Schedule I Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share data) Below is a reconciliation of non-GAAP financial measures to the most directly comparable measures calculated and presented in accordance with U.S. ���PolyOne Investor Presentation�5th Annual Wells Fargo�Industrial and Construction Conference �May 8, 2014 �� Forward – Looking Statements Use of Non-GAAP Measures PolyOne Commodity to Specialty Transformation Confirmation of Our Strategy Strategy and Execution Drive Results PolyOne�At A Glance Mix Shift Highlights Specialty Transformation Proof of Performance & 2015 Goals Bridge to $2.50 Adjusted EPS by 2015 Innovation Drives Earnings Growth Unique and Innovative Solutions Debt Maturities & Pension Funding – 3/31/14 Free Cash Flow and Strong Balance Sheet �Fund Investment / Shareholder Return Why Invest In PolyOne?

S&P 500 -150% -50% 50% 150% 250% 350% 450% 550% POL S&P 500 All time high of $43.34 July 1st, 2014 PolyOne Corporation Page 9 2006 2014 YTD 2015 “Where we were” “Where we are” Target 1) Operating Income % Specialty: Global Color, Additives & Inks 1.7% 14.9% 12 – 16% Global Specialty Engineered Materials 1.1% 12.1% 12 – 16% Designed Structures & Solutions -- 7.6% 8 – 10% Performance Products & Solutions 5.5% 8.1% 9 – 12% Distribution 2.6% 6.2% 6 – 7.5% 2) Specialty Platform % of Operating Income 6.0% 65% 65 – 75% 3) ROIC* 5.0% 10.6% 15% 4) Adjusted EPS Growth N/A 37% Double Digit Expansion Proof of Performance & 2015 Goals *ROIC is defined as TTM adjusted OI divided by the sum of average debt and equity over a 5 quarter period PolyOne Corporation Page 10 32% Adjusted EPS CAGR from 2011 2015 EPS: $2.50 2011 EPS: $0.82 Continued Gross Margin Expansion Mergers & Acquisitions Spartech Accretion Incremental Share Buybacks Ongoing LSS Programs (50-100 bps/yr) Accelerated Innovation & Mix Improvement Several Levers to Drive Growth Mid Single Digit Revenue Growth PolyOne Corporation Page 11 Innovation Drives Earnings Growth *Percentage of Specialty Platform revenue from products introduced in last five years $20 $53 2006 2013 Research & Development Spending ($ millions) Specialty Platform Vitality Index Progression* 14% 31% 2006 2013 Specialty Platform Gross Margin % 20% 43% 2006 2013 Specialty Vitality Index Target ≥ 35% Vitality Products + 700 to 1000 bps PolyOne Corporation Page 12 Prototype Frame Opportunity Scale-up & Test Market Build Business Case Commercial Launch Phase 1 Phase 2 Phase 3 Phase 4 Phase 5 4 11 5 10 6 9 3 4 2 15 9 1 10 4 Breakthrough Platform Derivative A Rich Pipeline of Opportunity Number of Projects 25 14 19 17 18 93 Addressable Market ($ millions) TBD TBD $800 $450 $450 $1,700 PolyOne Corporation Page 13 Megatrends Aligned with Key End Markets Decreasing Dependence on Fossil Fuels Protecting the Environment Improving Health and Wellness Megatrend End Markets Globalizing and Localizing Health & Wellness Transportation Packaging Consumer PolyOne Corporation Page 14 60% 100% 20% 30% 40% 50% 60% 70% 80% 90% 100% 2008 2014 Pension Funding** As of September 30, 2014 Debt Maturities & Pension Funding – 9/30/14 Net Debt / EBITDA* = 1.7x $48 $317 $600 $0 $100 $200 $300 $400 $500 $600 $700 $800 2015 2020 2023 Debt Maturities As of September 30, 2014 ($ millions) Coupon Rates: 7.500% 7.375% 5.250% ** includes US-qualified pension plans only *TTM 9/30/2014 PolyOne Corporation Page 15 Free Cash Flow and Strong Balance Sheet Fund Investment / Shareholder Return Expanding our sales, marketing, and technical capabilities Targets that expand our: • Specialty offerings • End market presence • Geographic footprint • Operating Margin Synergy opportunities Adjacent material solutions Repurchased 1.5 million shares in Q3 2014 Repurchased 9.7 million shares since early 2013 10.3 million shares are available for repurchase under the current authorization Organic Growth Acquisitions Share Repurchases Dividends  Investing in operational and LSS initiatives (including synergy capture) Manufacturing alignment $0.16 $0.20 $0.24 $0.32 $0.40 $0.10 $0.20 $0.30 $0.40 $0.50 2011 2012 2013 2014 2015 Annual Dividend PolyOne Corporation Page 16 PolyOne Core Values Innovation Collaboration Excellence PolyOne Corporation Page 17 The New PolyOne: A Specialty Growth Company Why Invest In PolyOne?  Strong past performance demonstrates that our strategy and execution are working  Megatrends and emerging opportunities align with our strengths  Innovation and services provide differentiation, incremental pricing power, and competitive advantage  Strong and proven management team driving growth and performance  Addressable market exceeds $40 billion 1 Schedule I Reconciliation of Non-GAAP Financial Measures (Unaudited) (Dollars in millions, except per share data) Below is a reconciliation of non-GAAP financial measures to the most directly comparable measures calculated and presented in accordance with U.S. ��PolyOne Investor Presentation�Goldman Sachs 2014 US Emerging / SMID Cap Growth Conference�New York, NY�November 20, 2014�� Forward-Looking Statements Use of Non-GAAP Measures PolyOne Commodity to Specialty Transformation PolyOne�At A Glance Mix Shift Highlights Specialty Transformation Confirmation of Our Strategy Strategy and Execution Drive Results Proof of Performance & 2015 Goals 32% Adjusted EPS CAGR from 2011 Innovation Drives Earnings Growth A Rich Pipeline of Opportunity Megatrends Aligned with Key End Markets Debt Maturities & Pension Funding – 9/30/14 Free Cash Flow and Strong Balance Sheet �Fund Investment / Shareholder Return PolyOne Core Values Why Invest In PolyOne?

Buyer acknowledges that Seller has furnished to Buyer Material Safety Data sheets, which include warnings together with safety and health information concerning the Product and/or the containers for such Product. การรบัรองความปลอดภยั และสุขอนามยั ผูซื้7 อรบัทราบวา่ ผูข้ายไดส่้งมอบเอกสารขอ้มูลความปลอดภยั (Material Safety Data sheets) ใหแ้ก่ผูซื้7 อแลว้ ซึ(งรวมถึงขอ้ควรระวงัต่างๆ พรอ้มดว้ยขอ้มูลความปลอดภยัและสุขอนามยัเกี(ยวกบัสินคา้ และ/หรือบรรจุภณัฑข์องสินคา้ดงักล่าว ผูซ้ื7 อจะเผยแพรข่อ้มลูดงักลา่วเพื(อแจง้ ขอ้ควรระวงัเกี(ยวกบัอนัตรายต่างๆ ที(อาจเกดิขึ7 นแกบุ่คคลที( ผูซื้7 อพึงคาดหมายไดต้ามสมควรวา่อาจไดร้บัอนัตรายดงักล่าว รวมถงึ แต่ไม่จาํกดัเพียง ลกูจา้ง ตวัแทน ผูร้บัจา้ง และลูกคา้ของผูซื้7 อ ผูซ้ื7 อจะชดใชค้วามเสียหาย แกต้่าง และคุม้ครองผูข้ายใหป้ลอดพน้จากความรบัผิดทั7งปวงอนัเกิดจาก หรือเกี(ยวเนื(องกบัการที(ผูซื้7 อมิไดเ้ผยแพร่ขอ้มลูดงักล่าว รวมถึง แต่ไม่จาํกดัเพียง ความรบัผิดต่อการบาดเจ็บ การเจ็บป่วย การเสียชีวติ และความเสียหายต่อทรพัยสิ์น และค่าใชจ่้ายในการตรวจสอบ การฟ้องรอ้งดาํเนินคดี และค่าทนายความตามสมควร 11.